Effects of High-Dose Intravenous Buprenorphine in Experienced Opioid Abusers
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Sublingual buprenorphine, a long-acting, partial mu-opioid agonist, is as effective as methadone in the treatment of heroin dependence, with a better safety profile due to its antagonist activity. However, the safety of therapeutic doses (8 to 16 mg) that might be diverted for intravenous (i.v.) use has not been demonstrated. To evaluate the safety and possible ceiling effects of buprenorphine administered i.v. to experienced opioid users, buprenorphine was administered to 6 nondependent opioid abusers residing on a research unit; the doses tested, in separate sessions, were 12 mg buprenorphine sublingual, i.v./sublingual placebo, and escalating i.v. buprenorphine (2, 4, 8, 12, and 16 mg). Physiologic and subjective measures were collected for 72 hours post-drug administration. Buprenorphine minimally but significantly increased systolic blood pressure. Changes in heart rate or oxygen saturation among the 7 drug conditions were not statistically significant. The mean maximum decrease in oxygen saturation from baseline was greatest for the 8-mg i.v. dose. Buprenorphine produced positive mood effects, although with substantial variability among participants. Onset and peak effects occurred earlier following i.v. administration: peak i.v. effects occurred between 0.25 and 3 hours; peak sublingual effects occurred at 3 to 7 hours. Duration of effects varied among the outcome measures. The dose-response curves were flat for most parameters, particularly subjective measures. Side effects were mild except in one participant who experienced severe nausea and vomiting after the 12-mg i.v. dose. Buprenorphine appears to have a ceiling for cardiorespiratory and subjective effects and a high safety margin even when taken by the i.v. route.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 2×
“In particular, its subjective effects are virtually identical to those of morphine and methadone.(13,14) Unlike full agonists, however, buprenorphine has been shown in animal studies to have a ceiling on its respiratory-depressant effects.”
BackgroundResultClinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773 · cited 3×
“Under controlled, laboratory conditions, sublingual doses of buprenorphine up to 32 mg produced minimal respiratory depression in nondependent opioid users and a ceiling for subjective effects at doses between 8 and 12 mg.(14,26) The safety and efficacy of directly observed therapy with high doses of sublingual bupren…”
BackgroundSelf-citationA Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10510-7 · Cited by 283
Self-citationCo-abuse of opiates and benzodiazepines
Rooney, S., Kelly, G., Bamford, L., Sloan, D., & O’Connor, J. J. (1999) · Irish Journal of Medical Science · doi:10.1007/bf02939579 · Cited by 70
Cited by
Buprenorphine: Considerations for Pain Management
Johnson, R. E., Fudala, P. J., & Payne, R. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.005 · Cited by 290
Kraus, M. L., Alford, D. P., Kotz, M. M., Levounis, P., Mandell, T. W., Meyer, M., Salsitz, E. A., Wetterau, N., & Wyatt, S. A. (2011) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182312983 · Cited by 266
Naltrexone and buprenorphine combination in the treatment of opioid dependence
Gerra, G., Fantoma, A., & Zaimovic, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060835 · Cited by 106
“In agreement with these findings, a recent study has indicated that buprenorphine produces positive mood effects, although with substantial variability among participants (Umbricht et al., 2004), probably in relationship to personality traits and underlying biological correlates.”
ResultBuprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study
Gerra, G., Leonardi, C., D'Amore, A., Strepparola, G., Fagetti, R., Assi, C., Zaimovic, A., & Lucchini, A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.10.007 · Cited by 88
“Accordingly, a recent study has indicated that BUP produces positive mood effects, although with substantial variability among participants ( Umbricht et al., 2004 ), probably in relationship with personality traits and underlying biological correlates.”
Background
Metadata
- Authors
- Umbricht, A., Huestis, M. A., Cone, E. J., & Preston, K. L.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2004-10
- Volume
- 24
- Issue
- 5
- Pages
- 479-487
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2021994694
- Cited by
- 49
- References
- 5
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of High-Dose Intravenous Buprenorphine in Experienced Opioid Abusers. https://app.cochat.ai/papers/10.1097/01.jcp.0000138766.15858.c6
- The paper
- Umbricht, A., Huestis, M. A., Cone, E. J., & Preston, K. L. (2004). Effects of High-Dose Intravenous Buprenorphine in Experienced Opioid Abusers. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000138766.15858.c6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.